Buy & Sell Ally Financial Inc (ALLY) – Ally Financial Inc Price Today
Aura AI Summary
Key Stats
- $12.98BMarket Cap
- FinancialsSector
- -11.77%3M Drawdown
- -Enterprise Value
- 2.83%Dividend Yield
- 66 daysTypical Hold Time
Ally Financial Inc (ALLY) is currently valued at a market capitalization of $12.98B. Over the past 52 weeks, Ally Financial Inc has traded between a low of $33.58 and a high of $47.06, highlighting its annual price range. Over the past three months, Ally Financial Inc has recorded a drawdown of -11.77%, reflecting recent price volatility. Ally Financial Inc offers a dividend yield of 2.83%, with the most recent dividend of $0.30 paid on 01 May 26. On average, investors hold Ally Financial Inc for approximately 66 days, indicating typical investor behavior on the platform.
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Most Recent News
CBAK Energy unveils advanced LFP cylindrical batteries boosting Southeast Asia's electric mobility.
CBAK Energy Technology showcased its innovative lithium-ion and sodium-ion cylindrical batteries designed for Southeast Asia's electric two- and three-wheelers at Autotech & Accessories 2026. Their batteries feature long life, high reliability, and s...

WeRide and Renault deploy autonomous Robobus at Roland-Garros for third year, expanding night service.
WeRide and Renault Group continue their partnership by operating the autonomous Robobus shuttle service at the Roland-Garros tennis tournament for the third consecutive year. The service runs a 2.8 km route connecting key points around the stadium, o...

Eli Lilly's gene therapy VERVE-102 cuts LDL cholesterol by up to 62% with lasting effects.
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
